🇺🇸 FDA
Pipeline program

Riociguat

BRWEP2024W112030108

Phase 3 small_molecule active

Quick answer

Riociguat for Chronic Thromboembolic Pulmonary Hypertension is a Phase 3 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Chronic Thromboembolic Pulmonary Hypertension
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials